Correvio Pharma Corp

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

NASDAQ: CORV TSX: CORV VANCOUVER, May 21, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme...

Correvio Obtains Final Order for Plan of Arrangement

Securityholders Approve ADVANZ PHARMA Acquisition NASDAQ: CORV TSX: CORV VANCOUVER, May 15, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), today announced the results of voting on matters considered at its annual general and special...

Correvio Announces Results from Annual General and Special Meeting of Securityholders

Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Correvio Pharma (CORV) Report Negative Q1 Earnings? What You Should Know

Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates

Will Correvio Pharma (CORV) Report Negative Q4 Earnings? What You Should Know

Shares of Canadian specialty pharma Correvio Pharma Corp (NASDAQ: CORV) are retreating in reaction to an adverse FDA verdict.

FDA Gives Thumbs Down To Correvio's Atrial Fibrillation Drug

Shares of microcap Correvio Pharma Corp. CORV, +14.57% slid about 12% in premarket trade Tuesday, after the company said it has received a Complete Response Letter from the U.S.

Microcap Correvio Pharma stock slammed after FDA rejects anti-arrhythmic drug

Correvio Pharma Corp. (NASDAQ: CORV) shares were crushed after the firm announced the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) decision for its New Drug Application (NDA) seeking approval for Brinavess.

Is This Atrial Fibrillation Drug Done For After FDA Vote?

Shares of Correvio Pharma CORV, +7.69% tumbled 54% in premarket trading after the specialty drugmaker said it was considering a sale of the company or its assets.

Correvio Pharma to consider a sale after FDA adcomm vote

Correvio Pharma Corp 
CORV
 shares came under selling pressure Friday after a briefing document released ahead of the company's planned Adcom meeting showed that FDA staffers were not convinced that the benefits of its atrial fibrillation medication Brinavess outweigh the risks.

Correvio Pharma In The Spotlight Ahead of Brinavess Adcom Verdict

Shares of Correvio Pharma Corp.  were halted in advance of a Food and Drug Administration advisory committee meeting for its experimental atrial fibrillation therapy.

Correvio stock halted ahead of FDA adcomm

Correvio Pharma's (CORV) CEO Mark Corrigan on Q3 2019 Results - Earnings Call Transcript

Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q2 2019 Results - Earnings Call Transcript

Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q1 2019 Results - Earnings Call Transcript

News for Correvio Pharma Corp Stock (CORV)